Please login first
Cristina Suárez  - - - 
Top co-authors See all
Alan R. Katritzky

234 shared publications

Ahmad Awada

91 shared publications

Antonio Oliver

90 shared publications

Microbiology Service, Hospital Son Espases, Palma de Mallorca, Spain

J. Salas

86 shared publications

Stefano Indraccolo

57 shared publications

Publication Record
Distribution of Articles published per year 
(1999 - 2016)
Total number of journals
published in
Publications See all
Conference 1 Read 0 Citations Mapping coffee producers’ transition to cocoa as a response to global change: smallholders’ water needs and adaptation i... Sonia Quiroga, Cristina Suarez, Juan Diego Solís, Pablo Mart... Published: 22 November 2016
The 1st International Electronic Conference on Water Sciences, doi: 10.3390/ecws-1-e004
DOI See at publisher website
Article 1 Read 0 Citations Impacto de la incorporación de la enfermera a una unidad de enfermedad inflamatoria intestinal Leticia Amo, Yago González-Lama, Cristina Suárez, Isabel Blá... Published: 01 May 2016
Gastroenterología y Hepatología, doi: 10.1016/j.gastrohep.2015.09.004
DOI See at publisher website
PubMed View at PubMed
ABS Show/hide abstract
Multidisciplinary units are needed because of the growing complexity and volume of patients with inflammatory bowel disease (IBD).
Article 1 Read 16 Citations Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients Gabriela Jiménez-Valerio, Mar Martínez-Lozano, Nicklas Bassa... Published: 01 May 2016
Cell Reports, doi: 10.1016/j.celrep.2016.04.015
DOI See at publisher website
PubMed View at PubMed
ABS Show/hide abstract
•Resistance to antiangiogenic therapy involves metabolic symbiosis patterning in RCC•mTOR pathway mediates this resistance and mTOR inhibition blocks metabolic symbiosis•In patients, antiangiogenics induce symbiotic patterning mostly in resistant tumors•mTOR pathway implication is also suggested in patients treated with antiangiogenics SummaryAntiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, and resistance eventually develops concomitant with progression. Here, we implicate metabolic symbiosis between tumor cells distal and proximal to remaining vessels as a mechanism of resistance to antiangiogenic therapies in patient-derived RCC orthoxenograft (PDX) models and in clinical samples. This metabolic patterning is regulated by the mTOR pathway, and its inhibition effectively blocks metabolic symbiosis in PDX models. Clinically, patients treated with antiangiogenics consistently present with histologic signatures of metabolic symbiosis that are exacerbated in resistant tumors. Furthermore, the mTOR pathway is also associated in clinical samples, and its inhibition eliminates symbiotic patterning in patient samples. Overall, these data support a mechanism of resistance to antiangiogenics involving metabolic compartmentalization of tumor cells that can be inhibited by mTOR-targeted drugs.
Article 1 Read 0 Citations Impact of the incorporation of a nurse in an inflammatory bowel disease unit Leticia Amo, Yago González-Lama, Cristina Suárez, Isabel Blá... Published: 01 May 2016
Gastroenterología y Hepatología (English Edition), doi: 10.1016/j.gastre.2016.04.006
DOI See at publisher website
Article 2 Reads 3 Citations Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer Neeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez, Nancy... Published: 18 April 2016
The Oncologist, doi: 10.1634/theoncologist.2015-0502
DOI See at publisher website
PubMed View at PubMed
ABS Show/hide abstract
Lessons Learned Despite evidence for a role for prolactin signaling in breast and prostate tumorigenesis, a prolactin receptor-binding monoclonal antibody has not produced clinical efficacy. Increased serum prolactin levels may be a biomarker for prolactin receptor inhibition. Results from the pharmacokinetic and pharmacodynamics (PD) studies suggest that inappropriately long dosing intervals and insufficient exposure to LFA102 may have resulted in lack of antitumor efficacy. Based on preclinical data, combination therapy of LFA102 with those novel agents targeting hormonal pathways in metastatic castration-resistant prostate cancer and metastatic breast cancer is promising. Given the PD evidence of prolactin receptor blockade by LFA102, this drug has the potential to be used in conditions such as hyperprolactinemia that are associated with high prolactin levels. Background. Prolactin receptor (PRLR) signaling is implicated in breast and prostate cancer. LFA102, a humanized monoclonal antibody (mAb) that binds to and inhibits the PRLR, has exhibited promising preclinical antitumor activity. Methods. Patients with PRLR-positive metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (mCRPC) received doses of LFA102 at 3–60 mg/kg intravenously once every 4 weeks. Objectives were to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) to investigate the safety/tolerability of LFA102 and to assess pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity. Results. A total of 73 patients were enrolled at 5 dose levels. The MTD was not reached because of lack of dose-limiting toxicities. The RDE was established at 60 mg/kg based on PK and PD analysis and safety data. The most common all-cause adverse events (AEs) were fatigue (44%) and nausea (33%) regardless of relationship. Grade 3/4 AEs reported to be related to LFA102 occurred in 4% of patients. LFA102 exposure increased approximately dose proportionally across the doses tested. Serum prolactin levels increased in response to LFA102 administration, suggesting its potential as a biomarker for PRLR inhibition. No antitumor activity was detected. Conclusion. Treatment with LFA102 was safe and well tolerated, but did not show antitumor activity as monotherapy at the doses tested.
Article 1 Read 0 Citations Do Water Rights Affect Technical Efficiency and Social Disparities of Crop Production in the Mediterranean? The Spanish ... Sonia Quiroga, Zaira Fernández-Haddad, Cristina Suárez Published: 03 November 2014
Water, doi: 10.3390/w6113300
DOI See at publisher website
ABS Show/hide abstract
The coming agenda for the European Common Agricultural Policy includes more incentives for the environmental compliance of farmer’s activities. This will be particularly important in the case of water risk management in Mediterranean countries. Among the new challenges is the need to evaluate some of the instruments necessary to comply with the Water Framework Directive requirements that emphasize the management of water demand to achieve the environmental targets. Here we analyze the implications of changing water rights as a policy response to these challenges. We analyze two important aspects of the decision: (i) the effects on the crop productivity and efficiency and (ii) the effects on the rural income distribution. We provide the empirical estimations for the marginal effects on the two considered aspects. First, we calculate a stochastic frontier production function for five representative crops using historical data to estimate technical efficiency. Second, we use a decomposition of the Gini coefficient to estimate the impact of irrigation rights changes on yield disparity. In our estimates, we consider both bio-physical and socio-economic aspects to conclude that there are long term implications on both efficiency and social disparities. We find disparities in the adaptation strategies depending on the crop and the region analyzed.